Imaging

Cardiology in the Spotlight: Enterprise Imaging That Goes Beyond Radiology

The future of medical imaging is about connection. Today’s healthcare challenges demand platforms that unify radiology, cardiology, digital pathology, genomics, and beyond into a seamless enterprise ecosystem—moving past the era of standalone systems and isolated workflows. A complete enterprise imaging solution allows us to move closer to an improved multidisciplinary collaboration, and a more comprehensive patient overview. And this is where cardiology becomes a key component in a future proof and modern enterprise imaging strategy.

Proven excellence in radiology: Sectra, known for their leadership in radiology, have been named “Best in KLAS” for PACS 12 years in a row. But Sectra isn’t a one-trick pony. They’re building solutions that go far beyond radiology to unify diagnostics, helping healthcare teams break down silos and work together more effectively.

Innovation across specialties

  • Digital pathology leadership: Through partnership with Leica Biosystems, Sectra is the only IMS (Image Management System) with FDA clearance for primary diagnostics using DICOM in digital pathology. Unifying radiology and pathology data on a single platform enables true integrated diagnostics, enhancing cross-specialty collaboration and tumor board reviews.
  • Groundbreaking genomics integration: Last year marked another milestone with the launch of Sectra Genomics—an industry first within an enterprise imaging platform. This advancement allows healthcare providers to combine molecular and imaging insights, enabling precision medicine particularly in oncology care.

The next generation of cardiology imaging

As healthcare becomes increasingly integrated, Sectra continues to build on their foundation of success and to push boundaries by transforming cardiovascular workflows. Sectra Cardiology Imaging addresses the long-standing challenge of fragmented cardiac imaging by unifying ECGs, Echo, Cath, Cardiac NM, Vascular, and CT FFR within a single, intuitive interface.

Introducing Sectra Echo Viewer

Coming Spring 2025, the Sectra Echo Viewer will transform echocardiogram workflows with:

  • Lightning-fast loading and crystal-clear playback
  • Same full diagnostic quality in Sectra IDS7 and Sectra UniView
  • Comprehensive measurement tools with structured reporting export
  • Multi-protocol support for TTE, TEE, vascular, and pediatric studies
  • Cloud-optimized design for easy access, quick launching, and future scalability

Through continuous innovation in enterprise imaging, Sectra enables healthcare organizations to deliver more confident diagnoses and better patient outcomes. Connected diagnostics is no longer a future promise, but a present reality.

Welcome to the next generation of Sectra Cardiology Imaging, and to the transformation of your cardiovascular workflow.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]